Animal anatomy

Kitchen Brains® launches USA2020 with $1+ million investment in Connecticut factory

Retrieved on: 
Wednesday, May 20, 2020
Animal anatomy, Brain, Organs, Kitchen, Humans

At the core of USA2020 is Kitchen Brains deep commitment to its manufacturing operations in the United States.

Key Points: 
  • At the core of USA2020 is Kitchen Brains deep commitment to its manufacturing operations in the United States.
  • With this investment, Kitchen Brains will provide customers with new capabilities, faster build times and greater accuracy.
  • In addition, the added capacity will enable Kitchen Brains to offer contract manufacturing to support current and new business partners in foodservice and other industries.
  • As the economy strengthens, Kitchen Brains will be well positioned to further lead the industry for controllers, monitors and new products that are currently in development."

Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19

Retrieved on: 
Monday, May 18, 2020
Animal anatomy, Brain, Organs

NOVATO, Calif., May 18, 2020 /PRNewswire/ -- Mercaptor Discoveries (Mercaptor), a platform company with preclinical programs in epilepsy and TBI, today announced that it is pivoting its proprietary neurotherapeutic development plan toward COVID-19.

Key Points: 
  • NOVATO, Calif., May 18, 2020 /PRNewswire/ -- Mercaptor Discoveries (Mercaptor), a platform company with preclinical programs in epilepsy and TBI, today announced that it is pivoting its proprietary neurotherapeutic development plan toward COVID-19.
  • Responding to the danger of brain damage caused by COVID-19, Mercaptor is directing its proprietary neurotherapeutic platform toward the development of drugs that prevent or relieve the worst effects of the virus.
  • "With Capton technology, injury-activated localized-treatment is now possible, allowing for precision medicine in the brain," said Sara Isbell, CEO, President and Co-Founder, Mercaptor Discoveries.
  • Mercaptor Discoveries was founded by a scientific team that has experience developing successful biotech companies, including Raptor Pharmaceuticals.

Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M

Retrieved on: 
Friday, May 15, 2020
Animal anatomy, Organ systems, Branches of biology, Bone marrow, Endocrine system, Hematopoiesis, Skeletal system

Overall case volume increased 43% in Q1-2020 vs. Q4-2019 due to an 87% increase in Peripheral Blood (PB) samples and a 17% increase in Bone Marrow samples from both new and existing customers.

Key Points: 
  • Overall case volume increased 43% in Q1-2020 vs. Q4-2019 due to an 87% increase in Peripheral Blood (PB) samples and a 17% increase in Bone Marrow samples from both new and existing customers.
  • Recurring customers that ordered each month during the quarter increased 16% in Q1-2020 vs. Q4-2019 and increased 61% vs. Q1-2019.
  • Additionally, the increase of PB cases vs. the lower growth of BM cases as mentioned in Metric #2 impacted the ARPU.
  • This increase was driven by the improved performance from our newer sales representatives and the addition of the Oncometrix sales team.

Global Exoskeleton Industry, 2027 - Introduction of New Composite Materials for Better Performance

Retrieved on: 
Monday, May 11, 2020
Animal anatomy, Biomechanics, Exoskeleton, Skeletons

According to this market research report, the exoskeleton market is expected to grow at a CAGR of 48.4% from 2019 to reach $11.4 billion by 2027.

Key Points: 
  • According to this market research report, the exoskeleton market is expected to grow at a CAGR of 48.4% from 2019 to reach $11.4 billion by 2027.
  • In addition, the replacement of conventional prosthetics with exoskeleton technology and increasing adoption of human augmentation in industrial and other end-use sectors provides significant opportunities for the exoskeleton market players.
  • Based on product type, the rigid exoskeleton segment accounted for the largest share of the overall exoskeleton market in 2019.
  • Geographically, North America commanded the largest share of the global exoskeleton market in 2019.

truSculpt® flex From Cutera, Inc. Wins 2020 Good Housekeeping Award

Retrieved on: 
Monday, May 4, 2020
Abdomen, Animal anatomy, Human anatomy

BRISBANE, Calif., May 4, 2020 /PRNewswire/ -- CUTERA, INC. , (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, proudly announces that truSculpt flex is a Good Housekeeping2020 Beauty Award Winner for Ultimate Body Product.

Key Points: 
  • BRISBANE, Calif., May 4, 2020 /PRNewswire/ -- CUTERA, INC. , (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, proudly announces that truSculpt flex is a Good Housekeeping2020 Beauty Award Winner for Ultimate Body Product.
  • The non-invasive, no-downtime treatment builds noticeable strength and visible toning results in 45 minutes with as little as four treatments.
  • The muscle sculpting technology underwent rigorous testing by Good Housekeeping's seasoned team of experts, earning the honor of Ultimate Body Product in the professional treatment category.
  • truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen.

MLB Player Inspired Baseball Fan To Save Life Of Leukemia Patient During Pandemic

Retrieved on: 
Wednesday, April 29, 2020
Medical specialties, Baseball players, Animal anatomy, Stem cells, Gift of Life Marrow Registry, Matt Szczur, Bone marrow, Leukemia

The 23-year-old was inspired by his hero and MLB professional baseball player Matt Szczur, who, in 2009 donated bone marrow to a young leukemia patient he had never met.

Key Points: 
  • The 23-year-old was inspired by his hero and MLB professional baseball player Matt Szczur, who, in 2009 donated bone marrow to a young leukemia patient he had never met.
  • So, in November 2016, Jackson searched the internet and found Gift of Life Marrow Registry.
  • He ordered a swab kit online and three years later he was called as a match for a patient battling leukemia.
  • "To learn about the ripple effect of not only helping to save a life, but also inspiring Drake to do the same, is truly amazing.

Q2Earth’s Bioscience Subsidiary, QSAM Therapeutics, Signs License for Promising Drug to Treat Bone Cancer

Retrieved on: 
Tuesday, April 28, 2020
Animal anatomy, Organ systems, Branches of biology, Stem cells, Queued Sequential Access Method, Bone marrow

(OTCQB: QPWR) (the Company or Q2) announced today that its wholly-owned subsidiary, QSAM Therapeutics Inc. (QSAM), has signed a Patent and Technology License Agreement and Trademark Assignment with IGL Pharma, Inc. (IGL).

Key Points: 
  • (OTCQB: QPWR) (the Company or Q2) announced today that its wholly-owned subsidiary, QSAM Therapeutics Inc. (QSAM), has signed a Patent and Technology License Agreement and Trademark Assignment with IGL Pharma, Inc. (IGL).
  • The License Agreement also provides QSAM a first right of refusal for other IGL/ISO technologies.
  • Initial indications for Samarium-153 DOTMP include bone marrow ablation, a pre-transplant procedure used to treat various diseases including cancer, immune system disorders and blood diseases including sickle cell disease.
  • About QSAM: QSAM Therapeutics Inc., a newly formed subsidiary of Q2Earth, holds the worldwide license for Samaium-153 DOTMP, a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases.

Outlook on the Worldwide Gaucher Disease Treatment Industry to 2027 - Europe Accounted for Around 28% Market Share in 2018 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 28, 2020
Genetics, Pharmaceutical, Health, Lipid storage disorders, Organs, Rare diseases, Branches of biology, Medical specialties, Animal anatomy, Gaucher's disease, Glucocerebrosidase, Gaucher, Glucocerebroside, Spleen, Liver

The "Global Gaucher Disease Treatment Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gaucher Disease Treatment Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering.
  • Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen.
  • The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e.
  • Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Global Exoskeleton Industry (2019 to 2027) - Replacement of Conventional Prosthetics with Exoskeleton Technology Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, April 27, 2020
Biotechnology, Health, Medical devices, Animal anatomy, Biomechanics, Market structure, Exoskeleton, Skeletons, Market share, Academic disciplines

According to this report the exoskeleton market is expected to grow at a CAGR of 48.4% from 2019 to reach $11.4 billion by 2027.

Key Points: 
  • According to this report the exoskeleton market is expected to grow at a CAGR of 48.4% from 2019 to reach $11.4 billion by 2027.
  • In addition, the replacement of conventional prosthetics with exoskeleton technology and increasing adoption of human augmentation in industrial and other end-use sectors provides significant opportunities for the exoskeleton market players.
  • The study also evaluates industry competitors and analyses their market share at global and regional level.
  • Based on product type, the rigid exoskeleton segment accounted for the largest share of the overall exoskeleton market in 2019.

FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

Retrieved on: 
Wednesday, April 15, 2020
Anatomy, Carcinoma, Transitional cell carcinoma, Organ systems, Animal anatomy, Transitional epithelium, Aging-associated diseases, RTT, Kidney, Ureter, Cancer, Urinary system

SILVER SPRING, Md., April 15, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Jelmyto (mitomycin gel), the first therapy to treat low-grade upper tract urothelial cancer (UTUC).

Key Points: 
  • SILVER SPRING, Md., April 15, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Jelmyto (mitomycin gel), the first therapy to treat low-grade upper tract urothelial cancer (UTUC).
  • Urothelial cancer is a cancer of the lining of the urinary system.
  • Our staff is continuing to meet virtually with drug developers, academic investigators and patient advocates to push forward the coordinated review of drugs, biologics and devices for cancer."
  • UTUC can block the ureter or kidney, causing swelling, infections and impairment of kidney function in some patients.